Surrozen (NASDAQ:SRZN) Director Purchases $51,240.00 in Stock

January 21, 2026 by InsiderTrades.com

Key Points

Director Tim Kutzkey bought 2,562 shares on Jan. 16 for $51,240 and made multiple additional open‑market purchases (including Jan. 15 and Jan. 20), bringing his direct stake to roughly 1.0–1.02 million shares valued at about $20 million.
Company fundamentals remain weak: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected), just $0.98M in revenue for the quarter and deeply negative margins and ROE, which temper the bullish signal from insider buying.

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey bought 2,562 shares of Surrozen stock in a transaction dated Friday, January 16th. The shares were bought at an average price of $20.00 per share, for a total transaction of $51,240.00. Following the completion of the transaction, the director directly owned 1,007,090 shares of the company's stock, valued at $20,141,800. This represents a 0.26% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Tim Kutzkey also recently made the following trade(s):

On Tuesday, January 20th, Tim Kutzkey purchased 18,052 shares of Surrozen stock. The stock was bought at an average cost of $19.60 per share, with a total value of $353,819.20.
On Thursday, January 15th, Tim Kutzkey acquired 11,893 shares of Surrozen stock. The shares were purchased at an average cost of $19.89 per share, for a total transaction of $236,551.77.
On Wednesday, January 14th, Tim Kutzkey acquired 5,523 shares of Surrozen stock. The stock was purchased at an average price of $19.99 per share, for a total transaction of $110,404.77.
On Tuesday, January 13th, Tim Kutzkey bought 12,470 shares of Surrozen stock. The stock was purchased at an average cost of $19.80 per share, with a total value of $246,906.00.
On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The shares were purchased at an average cost of $19.89 per share, for a total transaction of $300,339.00.
On Friday, December 5th, Tim Kutzkey acquired 30,884 shares of Surrozen stock. The stock was purchased at an average price of $19.54 per share, with a total value of $603,473.36.
On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The shares were purchased at an average cost of $17.35 per share, with a total value of $91,365.10.
On Thursday, November 13th, Tim Kutzkey bought 315,457 shares of Surrozen stock. The shares were acquired at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

Shares of NASDAQ:SRZN opened at $17.98 on Wednesday. The stock has a market cap of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. The company has a 50 day moving average of $18.98 and a 200-day moving average of $14.13. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94.

Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The business had revenue of $0.98 million during the quarter. Equities research analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Trading of Surrozen

Several hedge funds have recently bought and sold shares of the stock. Stempoint Capital LP lifted its stake in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock valued at $6,138,000 after buying an additional 445,713 shares in the last quarter. Braidwell LP acquired a new stake in shares of Surrozen during the second quarter worth $1,252,000. Millennium Management LLC bought a new stake in Surrozen in the 3rd quarter valued at $1,414,000. Schonfeld Strategic Advisors LLC acquired a new position in Surrozen in the 3rd quarter worth $889,000. Finally, Armistice Capital LLC bought a new position in Surrozen during the 2nd quarter worth about $536,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRZN has been the subject of a number of recent analyst reports. Lifesci Capital upgraded Surrozen to a "strong-buy" rating in a report on Thursday, November 13th. Wall Street Zen upgraded shares of Surrozen to a "sell" rating in a research report on Friday, November 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Surrozen in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $32.00.

Read Our Latest Analysis on Surrozen

Key Headlines Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

Positive Sentiment: Director Tim Kutzkey completed three open‑market buys on Jan 15, Jan 16 and Jan 20 totaling 32,507 shares (~$641k at the reported prices). After the trades he directly owns ~1.02M shares (≈$19.9M value), a roughly 1–1.8% increase in his position; insider buys can be read as a vote of confidence by management. SEC filing — Kutzkey purchases
Positive Sentiment: Major shareholder Group Gp Lp Column III mirrored the same purchases (Jan 15, 16, 20) for the same share counts and prices, increasing its stake to ~1.02M shares; large‑holder buying reinforces the insider signal and suggests continued institutional support. SEC filing — Group purchases
Neutral Sentiment: The transactions were disclosed via routine SEC beneficial‑ownership filings; they do not change reported board composition or indicate corporate action (e.g., buyback or financing) beyond increased insider/holder positions. SEC website
Negative Sentiment: Fundamentals remain a headwind: Surrozen reported a large Q3 earnings miss (EPS -$3.61 vs. -$1.17 expected) and minimal revenue, leaving the company with deep losses — this weak financial profile is the likely driver of downward pressure on the stock despite insider buying. MarketBeat — SRZN profile

About Surrozen

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.